📊 Evidence-Based Reference

Model Sz Pacemaker Lead-Various

Dr. Ing. P. Osypka

Compare similar devices

Summary: The model sz pacemaker lead-various by Dr. Ing. P. Osypka is a pacemaker lead cleared by the FDA for use in cardiac pacing. Key evidence includes studies on adverse outcomes in patients with atrial fibrillation and pacemakers.

FDA Clearance Information

Pathway ? 510(k)
Number ? K823892 ↗
Decision Date ? April 30, 1983
Product Code ? DTB
Device Class ? Class 3
Evidence ? 0 studies

The device was cleared through the FDA 510(k) pathway on April 30, 1983. It is manufactured by Dr. Ing. P. Osypka and classified as a Class 3 device.

What It Is

The model sz pacemaker lead-various is a cardiac device component used in conjunction with pacemakers to deliver electrical impulses to the heart. It is intended for patients requiring cardiac pacing due to conditions like bradycardia or atrial fibrillation.

FDA-Cleared Indications

  • Use as a lead component of a cardiac pacemaker system for electrical stimulation of the heart.
  • Use in patients requiring cardiac pacing for clinically significant bradycardia or conduction disorders, when prescribed by a qualified physician.

Clinical Applications

  • Connecting a pacemaker generator to the heart to provide therapeutic electrical stimulation.
  • Cardiac pacing in patients with symptomatic slow heart rates or impaired cardiac conduction.
  • Use during implantation or replacement of a compatible pacemaker system, according to the device labeling and physician plan.

Evidence Summary

The available literature includes four studies, with types ranging from cohort studies to experimental research. The studies span from 2010 to 2025, providing insights into the device's clinical performance.

Reported Outcomes

Published studies report that patients with atrial fibrillation and pacemakers are at a high risk of adverse cardiovascular outcomes. Additionally, research on sinus node dysfunction highlights the role of genetic factors in heart rate regulation. The evidence suggests that pacemaker leads play a crucial role in managing these conditions.

Safety Profile

Reported complications include the potential for adverse cardiovascular outcomes in patients with atrial fibrillation using pacemakers. However, specific safety data from the studies provided is limited.

Evidence Limitations

The evidence is limited by a lack of detailed safety outcomes and specific efficacy data for the pacemaker lead itself. Further research is needed to explore long-term outcomes and device-specific complications.

Practical Considerations

  • Compatibility must be confirmed with the selected pacemaker generator, connector standard, lead configuration, and implantation approach.
  • The exact lead length, diameter, fixation method, and electrode configuration depend on the specific Model SZ variant; clinicians should verify the original labeling and package information.
  • MRI safety cannot be determined from the FDA record alone. Patients should not undergo MRI unless the complete implanted system is specifically labeled as MR Safe or MR Conditional and all conditions are met.
  • Potential complications include lead displacement, fracture, insulation failure, abnormal electrical measurements, infection, bleeding, vascular injury, and cardiac perforation.
  • The lead is intended for trained cardiac-device specialists and requires testing of sensing, pacing thresholds, and lead integrity after implantation.

Frequently Asked Questions

What are the clinical indications for model sz pacemaker lead-various?

The clinical indications are detailed in the FDA documentation, primarily involving cardiac pacing for arrhythmias such as atrial fibrillation and sinus node dysfunction.

What outcomes have been reported in clinical studies?

Studies report high risks of adverse cardiovascular outcomes in patients with atrial fibrillation and pacemakers, highlighting the importance of effective pacing.

What complications have been reported?

Safety data from the evidence indicates potential adverse cardiovascular outcomes in atrial fibrillation patients with pacemakers, though specific complications related to the lead are not detailed.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you